1
|
Miyamoto HD, Ikeda M, Ide T, Tadokoro T, Furusawa S, Abe K, Ishimaru K, Enzan N, Sada M, Yamamoto T, Matsushima S, Koumura T, Yamada KI, Imai H, Tsutsui H. Iron Overload via Heme Degradation in the Endoplasmic Reticulum Triggers Ferroptosis in Myocardial Ischemia-Reperfusion Injury. JACC Basic Transl Sci 2022; 7:800-819. [PMID: 36061338 PMCID: PMC9436815 DOI: 10.1016/j.jacbts.2022.03.012] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 03/16/2022] [Accepted: 03/16/2022] [Indexed: 10/25/2022]
Abstract
Ischemia-reperfusion (I/R) injury is a promising therapeutic target to improve clinical outcomes after acute myocardial infarction. Ferroptosis, triggered by iron overload and excessive lipid peroxides, is reportedly involved in I/R injury. However, its significance and mechanistic basis remain unclear. Here, we show that glutathione peroxidase 4 (GPx4), a key endogenous suppressor of ferroptosis, determines the susceptibility to myocardial I/R injury. Importantly, ferroptosis is a major mode of cell death in I/R injury, distinct from mitochondrial permeability transition (MPT)-driven necrosis. This suggests that the use of therapeutics targeting both modes is an effective strategy to further reduce the infarct size and thereby ameliorate cardiac remodeling after I/R injury. Furthermore, we demonstrate that heme oxygenase 1 up-regulation in response to hypoxia and hypoxia/reoxygenation degrades heme and thereby induces iron overload and ferroptosis in the endoplasmic reticulum (ER) of cardiomyocytes. Collectively, ferroptosis triggered by GPx4 reduction and iron overload in the ER is distinct from MPT-driven necrosis in both in vivo phenotype and in vitro mechanism for I/R injury. The use of therapeutics targeting ferroptosis in conjunction with cyclosporine A can be a promising strategy for I/R injury.
Collapse
Key Words
- AMI, acute myocardial infarction
- CsA, cyclosporine A
- CypD, cyclophilin D
- DXZ, dexrazoxane
- ER, endoplasmic reticulum
- Fer-1, ferrostatin-1
- GPx4, glutathione peroxidase 4
- H/R, hypoxia-reoxygenation
- HF, heart failure
- HO-1, heme oxygenase 1
- I/R, ischemia-reperfusion
- LP, lipid peroxide
- MPT, mitochondrial permeability transition
- MPT-driven necrosis
- RCD, regulated cell death
- STEMI, ST-segment elevation myocardial infarction
- cyclosporine A
- ferroptosis
- glutathione peroxidase 4
- ischemia-reperfusion injury
Collapse
Affiliation(s)
- Hiroko Deguchi Miyamoto
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Masataka Ikeda
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Tomomi Ide
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Tomonori Tadokoro
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Shun Furusawa
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Ko Abe
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kosei Ishimaru
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Nobuyuki Enzan
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Masashi Sada
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Taishi Yamamoto
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Shouji Matsushima
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Tomoko Koumura
- Department of Hygienic Chemistry and Medical Research Laboratories, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
| | - Ken-ichi Yamada
- Physical Chemistry for Life Science Laboratory, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | - Hirotaka Imai
- Department of Hygienic Chemistry and Medical Research Laboratories, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
| | - Hiroyuki Tsutsui
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
2
|
Veltman D, Wu M, Pokreisz P, Claus P, Gillijns H, Caluwé E, Vanhaverbeke M, Gsell W, Himmelreich U, Sinnaeve PR, Janssens SP. Clec4e-Receptor Signaling in Myocardial Repair After Ischemia-Reperfusion Injury. JACC Basic Transl Sci 2021; 6:631-646. [PMID: 34466750 PMCID: PMC8385568 DOI: 10.1016/j.jacbts.2021.07.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Revised: 07/02/2021] [Accepted: 07/02/2021] [Indexed: 01/02/2023]
Abstract
The role of the CLEC4E during myocardial healing after ischemia-reperfusion injury is unknown. CLEC4E deletion is associated with reduced cardiac injury, inflammation, and left ventricular structural and functional remodeling. CLEC4E is a promising target to modulate myocardial inflammation and enhance repair after ischemia-reperfusion injury.
The bacterial C-type lectin domain family 4 member E (CLEC4E) has an important role in sterile inflammation, but its role in myocardial repair is unknown. Using complementary approaches in porcine, murine, and human samples, we show that CLEC4E expression levels in the myocardium and in blood correlate with the extent of myocardial injury and left ventricular (LV) functional impairment. CLEC4E expression is markedly increased in the vasculature, cardiac myocytes, and infiltrating leukocytes in the ischemic heart. Loss of Clec4e signaling is associated with reduced acute cardiac injury, neutrophil infiltration, and infarct size. Reduced myocardial injury in Clec4e–/– translates into significantly improved LV structural and functional remodeling at 4 weeks’ follow-up. The early transcriptome of LV tissue from Clec4e–/– mice versus wild-type mice reveals significant upregulation of transcripts involved in myocardial metabolism, radical scavenging, angiogenesis, and extracellular matrix organization. Therefore, targeting CLEC4E in the early phase of ischemia-reperfusion injury is a promising therapeutic strategy to modulate myocardial inflammation and enhance repair after ischemia-reperfusion injury.
Collapse
Key Words
- ACS, acute coronary syndrome
- AMI, acute myocardial infarction
- ANOVA, analysis of variance
- CAD, coronary artery disease
- CLEC4E
- CLEC4E, C-type lectin domain family 4 member E
- CMC, cardiac myocyte
- Car3, carbonic anhydrase 3
- Cxcl2, CXC chemokine ligand 2
- Cxcr2, CXC chemokine receptor 2
- DAMP, damage-associated molecular pattern
- ECM, extracellular matrix
- ESV, end-systolic volume
- Efna2, ephrin A2
- Grk2, G protein–coupled receptor kinase 2
- I/R, ischemia-reperfusion
- LAD, left anterior descending coronary artery
- LV, left ventricular
- MPO, myeloperoxidase
- MRI, magnetic resonance imaging
- NS, not significant
- PRR, pattern recognition receptor
- RNA, ribonucleic acid
- SMC, smooth muscle cell
- STEMI, ST-segment elevation myocardial infarction
- TnT, troponin T
- WT, wild-type
- hs-TnI, high-sensitivity troponin I
- inflammation
- ischemia-reperfusion injury
- magnetic resonance imaging
- myocardial remodeling
- qRT-PCR, quantitative reverse transcription polymerase chain reaction
Collapse
Affiliation(s)
- Denise Veltman
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Ming Wu
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Peter Pokreisz
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Piet Claus
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Hilde Gillijns
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Ellen Caluwé
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Maarten Vanhaverbeke
- Department of Cardiovascular Diseases, University Hospital Leuven, Leuven, Belgium
| | - Willy Gsell
- Department of Imaging and Pathology, Biomedical MRI, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Uwe Himmelreich
- Department of Imaging and Pathology, Biomedical MRI, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Peter R. Sinnaeve
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
- Department of Cardiovascular Diseases, University Hospital Leuven, Leuven, Belgium
| | - Stefan P. Janssens
- Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
- Department of Cardiovascular Diseases, University Hospital Leuven, Leuven, Belgium
- Address for correspondence: Dr Stefan P. Janssens, Department of Cardiovascular Sciences, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
| |
Collapse
|
3
|
García RA, Lupisella JA, Ito BR, Hsu MY, Fernando G, Carson NL, Allocco JJ, Ryan CS, Zhang R, Wang Z, Heroux M, Carrier M, St-Onge S, Bouvier M, Dudhgaonkar S, Nagar J, Bustamante-Pozo MM, Garate-Carrillo A, Chen J, Ma X, Search DJ, Dierks EA, Kick EK, Wexler RR, Gordon DA, Ostrowski J, Wurtz NR, Villarreal F. Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction. ACTA ACUST UNITED AC 2021; 6:676-689. [PMID: 34466754 PMCID: PMC8385569 DOI: 10.1016/j.jacbts.2021.07.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 07/20/2021] [Accepted: 07/20/2021] [Indexed: 11/30/2022]
Abstract
MI leads to ischemic damage of myocardium and activation of inflammatory programs as part of the wound healing response. Selective activation of FPR2 on macrophages potentiates key cellular activities that enable wound healing. MI was induced in rodents to study the effects of treatment with BMS-986235, a selective small molecule agonist of FPR2. BMS-986235 stimulated proresolution macrophage activities, induced neutrophil apoptosis and clearance, improved LV and infarct structure, and preserved cardiac function post MI. The findings suggest that targeted activation of FPR2 can improve post-MI outcome and may diminish the development of HF.
Dysregulated inflammation following myocardial infarction (MI) leads to maladaptive healing and remodeling. The study characterized and evaluated a selective formyl peptide receptor 2 (FPR2) agonist BMS-986235 in cellular assays and in rodents undergoing MI. BMS-986235 activated G proteins and promoted β-arrestin recruitment, enhanced phagocytosis and neutrophil apoptosis, regulated chemotaxis, and stimulated interleukin-10 and monocyte chemoattractant protein-1 gene expression. Treatment with BMS-986235 improved mouse survival, reduced left ventricular area, reduced scar area, and preserved wall thickness. Treatment increased macrophage arginase-1 messenger RNA and CD206 receptor levels indicating a proresolution phenotype. In rats following MI, BMS-986235 preserved viable myocardium, attenuated left ventricular remodeling, and increased ejection fraction relative to control animals. Therefore, FPR2 agonism improves post-MI healing, limits remodeling and preserves function, and may offer an innovative therapeutic option to improve outcomes.
Collapse
Key Words
- BRET, bioluminescence resonance energy transfer
- EC50, half maximal effective concentration
- FPR2
- FPR2, formyl peptide receptor 2
- HF
- HF, heart failure
- I/R, ischemia-reperfusion
- IL, interleukin
- KO, knockout
- LPS, lipopolysaccharide
- LV, left ventricle/ventricular
- MCP, monocyte chemoattractant protein
- MI
- MI, myocardial infarction
- SAA, serum amyloid A
- TNF, tumor necrosis factor
- WT, wild-type
- formyl peptide receptor 2
- heart failure
- mRNA, messenger RNA
- myocardial infarction
- resolution
Collapse
Affiliation(s)
- Ricardo A García
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA.,Department of Medicine, University of California-San Diego, San Diego, California, USA
| | - John A Lupisella
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Bruce R Ito
- Department of Medicine, University of California-San Diego, San Diego, California, USA
| | - Mei-Yin Hsu
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Gayani Fernando
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Nancy L Carson
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - John J Allocco
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Carol S Ryan
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Rongan Zhang
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Zhaoqing Wang
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Madeleine Heroux
- Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada
| | - Marilyn Carrier
- Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada
| | - Stéphane St-Onge
- Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada
| | - Michel Bouvier
- Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada
| | | | - Jignesh Nagar
- Biocon Bristol Myers Squibb Research Center, Bangalore, India
| | | | | | - Jian Chen
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Xiuying Ma
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Debra J Search
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Elizabeth A Dierks
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Ellen K Kick
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Ruth R Wexler
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - David A Gordon
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Jacek Ostrowski
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Nicholas R Wurtz
- Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey, USA
| | - Francisco Villarreal
- Department of Medicine, University of California-San Diego, San Diego, California, USA
| |
Collapse
|
4
|
Abstract
Autosis is an autophagy-dependent, nonapoptotic, and non-necrotic form of cell death that is characterized by unique morphological and biochemical features, including the presence of ballooning of perinuclear space (PNS) and sensitivity to cardiac glycosides, respectively. Autotic cell death may be initiated by excessive accumulation of autophagosomes rather than lysosomal degradation. Autosis is stimulated during the late phase of reperfusion after a period of ischemia in the heart when up-regulation of rubicon in the presence of continuous autophagosome production induces massive accumulation of autophagosomes. Suppression of autosis, which may reduce death of cardiomyocytes during the late phase of reperfusion, in combination with inhibition of apoptosis and necrosis targeting the early phase of injury, may enhance the effectiveness of treatment for I/R injury in the heart.
Excessive autophagy induces a defined form of cell death called autosis, which is characterized by unique morphological features, including ballooning of perinuclear space and biochemical features, including sensitivity to cardiac glycosides. Autosis is observed during the late phase of reperfusion after a period of ischemia and contributes to myocardial injury. This review discusses unique features of autosis, the involvement of autosis in myocardial injury, and the molecular mechanism of autosis. Because autosis promotes myocardial injury under some conditions, a better understanding of autosis may lead to development of novel interventions to protect the heart against myocardial stress.
Collapse
Key Words
- ATG, autophagy-related
- ATPase, adenosine triphosphatase
- ER, endoplasmic reticulum
- HIV, human immunodeficiency virus
- I/R, ischemia-reperfusion
- LBR, lamin B receptor
- Na+,K+–adenosine triphosphatase
- PI3K, phosphatidylinositol 3 kinase
- PNS, perinuclear space
- Tat, transactivation of transcription
- autophagic cell death
- autophagic flux
- autosis
- beclin 1
- rubicon
Collapse
|
5
|
Watanabe M, Kaneko Y, Ohishi Y, Kinoshita M, Sakairi T, Ikeuchi H, Maeshima A, Saito Y, Ohnishi H, Nojima Y, Matozaki T, Hiromura K. Importance of methodology in the evaluation of renal mononuclear phagocytes and analysis of a model of experimental nephritis with Shp1 conditional knockout mice. Biochem Biophys Rep 2020; 22:100741. [PMID: 32154390 PMCID: PMC7057148 DOI: 10.1016/j.bbrep.2020.100741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2019] [Revised: 01/24/2020] [Accepted: 01/27/2020] [Indexed: 11/25/2022] Open
Abstract
Tissue resident mononuclear phagocytes (Mophs), comprising monocytes, macrophages, and dendritic cells (DCs), play important roles under physiological and pathological conditions. The presence of these cells in the kidney has been known for decades, and studies of renal Mophs (rMophs) are currently underway. Since no unified procedure has been identified to isolate rMophs, results of flow cytometric analysis of rMophs have been inconsistent among studies. We therefore first evaluated a preparative method for rMophs using collagenous digestion. The yield of rMophs greatly increased after the collagenase digestion. In particular, F4/80high rMophs, which were positive for CD11c, a specific marker of DCs, dramatically increased. In addition, since neutrophils are sometimes mixed among rMophs in the analysis of flow cytometry, we established a gating strategy for eliminating neutrophils. To determine the contribution of rMophs to the development of autoimmune nephritis, we analyzed an experimental model of autoimmune nephritis that was applied to Shp1 conditional knockout mice (Shp1 CKO). This knockout strain is generated by crossing a mouse line carrying floxed Shp1 allele to mice expressing Cre recombinase under the control of the CD11c promoter. Shp1 CKO therefore specifically lack Shp1 in cells expressing CD11c. As a result, Shp1 CKO were susceptible to that experimental glomerulonephritis and F4/80high rMophs of Shp1 CKO increased dramatically. In conclusion, our preparative methods for collagenase digestion and gating strategy for neutrophils are necessary for the analysis of rMophs, and Shp1 suppresses the development of autoimmune nephritis through the control of rMophs.
Collapse
Affiliation(s)
- Mitsuharu Watanabe
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Yoriaki Kaneko
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Yuko Ohishi
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Masato Kinoshita
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Toru Sakairi
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Hidekazu Ikeuchi
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Akito Maeshima
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Yasuyuki Saito
- Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Hiroshi Ohnishi
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514, Japan
| | - Yoshihisa Nojima
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| | - Takashi Matozaki
- Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Keiju Hiromura
- Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
| |
Collapse
|
6
|
Sun K, Fan J, Han J. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. Acta Pharm Sin B 2015; 5:8-24. [PMID: 26579420 PMCID: PMC4629119 DOI: 10.1016/j.apsb.2014.11.002] [Citation(s) in RCA: 144] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 10/22/2014] [Accepted: 10/28/2014] [Indexed: 01/22/2023] Open
Abstract
Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global public health. These disorders are associated with multiple insults to the cerebral microcirculation, including reactive oxygen species (ROS) overproduction, leukocyte adhesion and infiltration, brain blood barrier (BBB) disruption, and capillary hypoperfusion, ultimately resulting in tissue edema, hemorrhage, brain injury and delayed neuron damage. Traditional Chinese medicine (TCM) has been used in China, Korea, Japan and other Asian countries for treatment of a wide range of diseases. In China, the usage of compound TCM preparation to treat cerebrovascular diseases dates back to the Han Dynasty. Even thousands of years earlier, the medical formulary recorded many classical prescriptions for treating cerebral I/R-related diseases. This review summarizes current information and underlying mechanisms regarding the ameliorating effects of compound TCM preparation, Chinese materia medica, and active components on I/R-induced cerebral microcirculatory disturbances, brain injury and neuron damage.
Collapse
Key Words
- 8-OHdG, 8-hydroxydeoxyguanosine
- AIF, apoptosis inducing factor
- AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- AP-1, activator protein-1
- Antioxidant
- Asp, aspartate
- BBB, brain blood barrier
- BMEC, brain microvascular endothelial cell
- BNDF, brain-derived neurotrophic factor
- Brain blood barrier
- CAT, catalase
- CBF, cerebral blood flow
- COX-2, cyclooxygenase-2
- Cav-1, caveolin-1
- DHR, dihydrorhodamine 123
- DPPH, 1,1-diphenyl-2-picrylhydrazyl radical 2,2-diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl
- ERK, extracellular signal-regulated kinase
- GABA, γ-aminobutyric acid
- GRK2, G protein-coupled receptor kinase 2
- GSH, glutathione
- GSH-Px, glutathione peroxidase
- GSSH, glutathione disulfide
- Glu, glutamate
- Gly, glysine
- HE, hematoxylin and eosin
- HIF, hypoxia-inducible factor
- HPLC, high performance liquid chromatography
- Hyperpermeability
- I-κBα, Inhibitory κBα
- I/R, ischemia-reperfusion
- ICAM-1, intercellular adhesion molecule-1
- IL-10, interleukin-10
- IL-1β, interleukin-1β
- IL-8, interleukin-8
- Ischemia/reperfusion
- JAM-1, junctional adhesion molecule-1
- JNK, Jun N-terminal kinase
- LDH, lactate dehydrogenase
- Leukocyte adhesion
- MAPK, mitogen activated protein kinase
- MCAO, middle cerebral artery occlusion
- MDA, malondialdehyde
- MMPs, matrix metalloproteinases
- MPO, myeloperoxidase
- MRI, magnetic resonance imaging
- NADPH, nicotinamide adenine dinucleotide phosphate
- NF-κB, nuclear factor κ-B
- NGF, nerve growth factor
- NMDA, N-methyl-d-aspartic acid
- NO, nitric oxide
- NSC, neural stem cells
- Neuron
- OGD, oxygen-glucose deprivation
- PARP, poly-ADP-ribose polymerase
- PMN, polymorphonuclear
- RANTES, regulated upon activation normal T-cell expressed and secreted
- ROS, reactive oxygen species
- SFDA, state food and drug administration
- SOD, superoxide dismutase
- TBARS, thiobarbituric acid reactive substance
- TCM, traditional Chinese medicine
- TGF-β1, transforming growth factor β1
- TIMP-1, tissue inhibitor of metalloproteinase-1
- TNF-α, tissue necrosis factor-α
- TTC, 2,3,5-triphenyltetrazolium chloride
- TUNEL, terminal-deoxynucleoitidyl transferase mediated nick end labeling
- Tuj-1, class III β-tublin
- VCAM-1, vascular adhesion molecule-1
- VEGF, vascular endothelial growth factor
- ZO-1, zonula occludens-1
- bFGF, basic fibroblast growth factor
- cAMP, cyclic adenosine monophosphate
- hs-CRP, high-sensitivity C-reactive protein
- iNOS, inducible nitric oxide synthase
- rtPA, recombinant tissue plasminogen activator
Collapse
|
7
|
Ghonem N, Yoshida J, Murase N, Strom SC, Venkataramanan R. Treprostinil Improves Hepatic Cytochrome P450 Activity during Rat Liver Transplantation. J Clin Exp Hepatol 2012; 2:323-32. [PMID: 25755454 PMCID: PMC3940493 DOI: 10.1016/j.jceh.2012.09.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2012] [Accepted: 09/30/2012] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Cytochrome P450 (CYP450) activity is an important indicator of liver graft function. CYP450 activity is altered by pro-inflammatory cytokines, which are associated with ischemia-reperfusion (I/R) injury during orthotopic liver transplantation (OLT). Treprostinil, an FDA-approved prostacyclin analog, ameliorated cold I/R injury during rat OLT. We hypothesized that treprostinil would improve CYP450 activity in liver graft during cold I/R injury post-OLT. METHODS OLT was performed in syngeneic male Lewis rats with 18 h graft preservation in cold UW solution. Donor and recipients received treprostinil (100 ng/kg/min) or matching placebo for 24 h before and up to 48 h post-OLT. Liver graft mRNA and protein expression of CYP450 isoforms were analyzed by qRT-PCR and Western blot analysis, respectively. The formation rates of 1-hydroxymidazolam and 6β-hydroxytestosterone, 6-hydroxychlorzoxazone, 2α- and 16α-hydroxytestosterone in liver graft microsomes served as markers for CYP3A, CYP2E1, and CYP2C11 activity, respectively, and were measured by LC-MS. RESULTS Treprostinil significantly decreased serum ALT and AST levels at 6-48 h after OLT, compared to placebo. The expressions of TNFα and IFNγ mRNA in the liver graft were significantly inhibited in the treprostinil-treated group at 1 h post-reperfusion. Treprostinil restored CYP2E1 protein expression to that of normal liver and significantly improved CYP3A activity to more than two-fold of placebo early post-OLT. CONCLUSIONS Treprostinil significantly ameliorated hepatic injury, reduced expression of pro-inflammatory cytokines, and improved CYP450 activity in liver graft early post-OLT. These findings suggest that treprostinil has the potential to serve as a therapeutic option to protect liver graft function against I/R injury during clinical OLT.
Collapse
Key Words
- 1-OH MDZ, 1-hydroxymidazolam
- 16α-OH TST, 16α-hydroxytestosterone
- 2α-OH TST, 2α-hydroxytestosterone
- 6-OH CZN, 6-hydroxychlorzoxazone
- 6β-OH TST, 6β-hydroxytestosterone
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- AUC, area under the time-concentration curves
- CYP450, cytochrome P450
- CZN, chlorzoxazone
- HPLC-mass spectrometry
- I/R, ischemia-reperfusion
- IFN-γ, interferon gamma
- IL, interleukin
- Ischemia-reperfusion injury
- MDZ, midazolam
- NF-κB, nuclear factor-kappa B
- NL, normal liver
- OLT, orthotopic liver transplantation
- PG, prostaglandin
- PGI2, prostacyclin
- TNF-α, tumor necrosis factor alpha
- TST, testosterone
- UW, University of Wisconsin
- cytokines
- drug metabolism
- mRNA, messenger RNA
- prostacyclin
Collapse
Affiliation(s)
- Nisanne Ghonem
- University of Pittsburgh School of Pharmacy, Department of Pharmaceutical Sciences, Pittsburgh, PA, USA,Address for correspondence: Nisanne Ghonem, Yale University School of Medicine, Digestive Diseases Section, TAC S230, USA. Tel.: +1 203 785 3150; fax: +1 203 785 7273.
| | - Junichi Yoshida
- School of Medicine, Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, USA
| | - Noriko Murase
- School of Medicine, Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, USA
| | - Stephen C. Strom
- Professor, Cellular Transplantation, Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet and Hospital, Stockholm 141-86, Sweden
| | - Raman Venkataramanan
- University of Pittsburgh School of Pharmacy, Department of Pharmaceutical Sciences, Pittsburgh, PA, USA,School of Medicine, Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, USA
| |
Collapse
|